Aligos Therapeutics Secures $25M Upfront in China Deal as HBV Pipeline Advances
Event summary
- Aligos Therapeutics received a $25M upfront payment from Amoytop for exclusive Greater China rights to pevifoscorvir sodium.
- Amoytop triggered a $3M milestone payment after receiving IND approval in China for ALG-170675, an ASO candidate for chronic HBV.
- Pevifoscorvir sodium's Phase 2 B-SUPREME study completed enrollment with topline data expected in late Q3 2027.
- Aligos' cash position stood at $30.4M as of June 30, 2026, excluding the $25M upfront payment received in July 2026.
The big picture
Aligos Therapeutics is strengthening its position in the chronic HBV treatment space through strategic partnerships and regulatory milestones. The $25M upfront payment from Amoytop underscores the value of pevifoscorvir sodium, while the IND approval for ALG-170675 expands Aligos' pipeline potential. With ~240 million patients worldwide suffering from chronic HBV, these advancements could position Aligos as a key player in addressing this significant unmet medical need.
What we're watching
- Regulatory Momentum
- Whether the Breakthrough Therapy Designation in China will accelerate pevifoscorvir sodium's path to market.
- Financial Runway
- How Aligos manages its cash position through 2026 with $30.4M on hand and increasing R&D expenses.
- Pipeline Synergy
- The potential for ALG-170675 to complement pevifoscorvir sodium in combination therapies, both in China and ex-China markets.
Related topics